Source: globenewswire_biotech
Source ID: globenewswire_biotech:https://www.globenewswire.com/news-release/2026/10/23/3387298/35550/en/xbiotech-announces-election-of-sushma-shivaswamy-and-jan-paul-simard-as-co-chief-executive-officers.html:XBIT
URL: https://www.globenewswire.com/news-release/2026/10/23/3387298/35550/en/xbiotech-announces-election-of-sushma-shivaswamy-and-jan-paul-simard-as-co-chief-executive-officers.html
Symbol: (XBIT)
Published: 2026-10-23 09:17:00 EDT
Time precision: minute
Title: XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

Accessibility: Skip TopNav
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
October 23, 2026 09:17 ET
| Source:
XBiotech Inc.
XBiotech Inc.
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
“On behalf of the Board of Directors, we are excited to announce Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers,”
said Director Tevi Troy. “Their complementary skill sets, scientific acumen, and shared commitment to our mission position XBiotech to fully realize the potential of our True-Human antibody therapies.”
Dr. Shivaswamy has been with XBiotech for 17 years, having served as Senior Scientist, Director and Vice President of Research & Development prior to her appointment as Chief Scientific Officer in 2017. As CSO, Dr. Shivaswamy oversaw scientific and technical operations spanning R&D through GMP production of antibodies. In December of 2025, Dr. Shivaswamy was named interim CEO following the retirement of Founder John Simard.
“
As our industry evolves, so must our approach to leadership,” said Dr. Shivaswamy. “Appointing Jan-Paul Simard as Co-CEO reflects our commitment to staying proactive, adaptive, and relentlessly focused on execution. He brings a distinct perspective and operational continuity that strengthens our decision-making. I look forward to working side-by-side to deliver lasting value to our patients and shareholders”.
Jan-Paul Simard started at XBiotech in 2012 as an R&D assistant before transitioning in 2020 to the clinical development team, where he contributed to study design and protocol development across clinical trials in pancreatic cancer, non-small cell lung cancer, osteoarthritis, and rheumatoid arthritis. He has continued his scientific education in Chemistry with Honours at the University of Saskatchewan, further strengthening his expertise in clinical and biological sciences.
“It is an honour to step into this leadership role at such a pivotal moment for XBiotech, especially in tandem with a scientist as accomplished as Dr. Shivaswamy,” said Mr. Simard. “Her leadership as interim CEO has positioned the company to capitalize on its pipeline of drug candidates, and I look forward to partnering with her and our talented team to advance new therapies.”
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ discovery platform. XBiotech currently is advancing antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit
www.xbiotech.com
.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Wenyi Wei
publicrelations@xbiotech.com
tel. 737-207-4600
Tags
biotechnology
Clinical Research
HEALTH
pharmaceutical
GlobeNewswire
Recommended Reading
October 24, 2026 08:07 ET
|
Source:
XBiotech Inc.
XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux
AUSTIN, Texas, 24 oct. 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui que son conseil d’administration avait élu Jan-Paul Simard au poste de co-directeur général, aux...
Read More
October 19, 2026 18:59 ET
|
Source:
XBiotech Inc.
XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire
L’étude sponsorisée par des chercheurs et financée par l’Institut National du Cancer (INCa) atteint le critère de jugement principal d’efficacité préspécifié, avec une survie globale à 12 mois de 61,3...
Read More
Explore
October 25, 2026 05:00 ET
KFSH Expands Virtual Care Pathways to Bring Specialized Follow-Up Closer to Patients
October 24, 2026 21:33 ET
Two Premium Tube Laser Cutting Machines Make European Debut as Bodor Laser Brings End-to-End Metal Fabrication Solutions to EuroBLECH 2026
October 24, 2026 18:49 ET
New Data 2026 On Rent, Buy, EMI or Second-Hand: What a Wardrobe Costs a Delhi Tenant Over an 11-Month Lease in 2026, as Rentomojo Prices a Mirrored Two-Door Cupboard at ₹312 a Month With Assembly, Repairs and the Next Move Included
October 24, 2026 13:56 ET
UK Financial Ltd Launches MAYA CHAIN and Begins Digital Asset Migration
October 24, 2026 13:38 ET
Rentomojo Reports Rising Demand for Bedroom Furniture Rental in Delhi as a Queen Bed, Mattress, Two-Door Wardrobe and Bedside Table Rent for About ₹1,250 a Month in 2026, Against ₹18,000 to Buy a Queen Bed Alone
❮
❯